ASH 2023 | Analysis of the IMerge trial: the disease-modifying potential of imetelstat in LR-MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares an analysis of the Phase III placebo-controlled IMerge trial (NCT02598661), assessing the efficacy of imetelstat in patients with transfusion-dependent low-risk myelodysplastic syndromes (LR-MDS) who are relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs). The trial revealed an 18% sustained transfusion-independence rate and favorable drug tolerability. Additionally, there was a decrease in mutational burden, suggesting the disease-modifying potential of the drug. Imetelstat is currently undergoing approval review for second-line treatment in LR-MDS. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Novartis, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Amgen, Curis, Geron, Silence Therapeutics, Takeda
Honoraria: Novartis, Jazz, Bristol Myers Squibb, Servier, Syros, Celgene, Silence Therapeutics, Takeda
Research Funding: Novartis, Roche, BeiGene, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Merck, Fibrogen, Amgen, Curis, Geron, BMS, Silence Therapeutics, Takeda
Board of Directors/Advisory Committee: MDS Foundation, Bristol Myers Squibb
Travel Support: Bristol Myers Squibb
Medical Writing Support: Bristol Myers Squibb
